{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T05:32:31Z","timestamp":1663651951900},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>This study is to investigate the effect of late-onset hemorrhagic cystitis (LOHC) on progression-free survival (PFS) of patients after haploidentical peripheral blood hematopoietic stem cell transplantation (haplo-PBSCT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study enrolled 74 patients with hematological malignancies treated with a myeloablative conditioning regimen and haplo-PBSCT. The effect of LOHC on PFS was studied in terms of HC occurrence, grade, disease type, duration, onset time, gender, and age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 28 patients with LOHC, and no case was with early-onset HC. The cumulative incidence of LOHC was 37.8% (95% CI: 26.9\u201348.7%). The 2-year expected PFS of 74 patients and 34 AML patients was not significantly different between LOHC patients and patients without HC (<jats:italic>P<\/jats:italic> &gt; 0.05). Among 27 ALL patients, the 2-year expected PFS of LOHC patients was 75%, significantly higher than patients without HC (54.2%) (<jats:italic>P<\/jats:italic> &lt; 0.05). The 2-year expected PFSs of patients with mild LOHC and severe LOHC were 69.8 and 77.8%, respectively (<jats:italic>P<\/jats:italic> &gt; 0.05). Similarly, the onset time, duration, age, and gender of LOHC patients did not show significant effects on PFS (<jats:italic>P<\/jats:italic> &gt; 0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>After haplo-PBSCT, LOHC has a significant effect on the PFS of ALL patients. The HC grade, duration, onset time, gender, and age have no significant effect on PFS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/med-2021-0368","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T23:49:37Z","timestamp":1633909777000},"page":"1493-1502","source":"Crossref","is-referenced-by-count":1,"title":["Effect of late-onset hemorrhagic cystitis on PFS after haplo-PBSCT"],"prefix":"10.1515","volume":"16","author":[{"given":"Hailong","family":"Yuan","sequence":"first","affiliation":[{"name":"Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology , Urumqi 830054 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology , Urumqi 830054 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Qu","sequence":"additional","affiliation":[{"name":"Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology , Urumqi 830054 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixue","family":"Yang","sequence":"additional","affiliation":[{"name":"Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology , Urumqi 830054 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Muhashi","sequence":"additional","affiliation":[{"name":"Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology , Urumqi 830054 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulibadanmu","family":"Aizezi","sequence":"additional","affiliation":[{"name":"Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology , Urumqi 830054 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology , No. 137 Liyushan South Road , Urumqi 830054 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"2022091918191485160_j_med-2021-0368_ref_001","doi-asserted-by":"crossref","unstructured":"Kaur D, Khan SP, Rodriguez V, Arndt P, Claus P. Hyperbaric oxygen as a treatment modality in cyclophosphamide-induced hemorrhagic cystitis. Pediatr Transpl. 2018;22:e13171.","DOI":"10.1111\/petr.13171"},{"key":"2022091918191485160_j_med-2021-0368_ref_002","doi-asserted-by":"crossref","unstructured":"Gander R, Asensio M, Guill\u00e9n G, Royo GF, Bolanos A, P\u00e9rez M, et al. Hemorrhagic cystitis after hematopoietic stem cell transplantation: a challenge for the pediatric urologist. J Pediatr Urol. 2018;14:366\u201373.","DOI":"10.1016\/j.jpurol.2018.03.018"},{"key":"2022091918191485160_j_med-2021-0368_ref_003","doi-asserted-by":"crossref","unstructured":"Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant. 2008;41:11\u20138.","DOI":"10.1038\/sj.bmt.1705886"},{"key":"2022091918191485160_j_med-2021-0368_ref_004","doi-asserted-by":"crossref","unstructured":"delaCruz J, Pursell K. BKVirus and its role in hematopoietic stem cell transplantation: evolution of a pathogen. Curr Infect Dis Rep. 2014;16:417.","DOI":"10.1007\/s11908-014-0417-x"},{"key":"2022091918191485160_j_med-2021-0368_ref_005","doi-asserted-by":"crossref","unstructured":"Umeda K, Kato I, Kawaguchi K, Tasaka K, Kamitori T, Ogata H, et al. High incidence of BK virus-associated hemorrhagic cystitis in children after second or third allogeneic hematopoietic stem cell transplantation. Pediatr Transpl. 2018;22:e13183.","DOI":"10.1111\/petr.13183"},{"key":"2022091918191485160_j_med-2021-0368_ref_006","doi-asserted-by":"crossref","unstructured":"Cesaro S, Dalianis T, Hanssen Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73:12\u201321.","DOI":"10.1093\/jac\/dkx324"},{"key":"2022091918191485160_j_med-2021-0368_ref_007","doi-asserted-by":"crossref","unstructured":"Kerbauy LN, Kerbauy MN, Bautzer V, Chapchap EC, de Mattos VRP, da Rocha JDA, et al. Severe hemorrhagic cystitis caused by the BK polyomavirus is associated with. decreased survival post-allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2019;21:e13101.","DOI":"10.1111\/tid.13101"},{"key":"2022091918191485160_j_med-2021-0368_ref_008","doi-asserted-by":"crossref","unstructured":"Uhm J, Hamad N, Michelis FV, Shanavas M, Kuruvilla J, Gupta V, et al. The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic. hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD. Bone Marrow Transplant. 2014;49:1528\u201334.","DOI":"10.1038\/bmt.2014.181"},{"key":"2022091918191485160_j_med-2021-0368_ref_009","doi-asserted-by":"crossref","unstructured":"Gilis L, Morisset S, Billaud G, Ducastelle-Lepr\u00eatre S, Labussi\u00e8re-Wallet H, Nicolini FE, et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49:664\u201370.","DOI":"10.1038\/bmt.2013.235"},{"key":"2022091918191485160_j_med-2021-0368_ref_010","doi-asserted-by":"crossref","unstructured":"Lunde LE, Dasaraju S, Cao Q, Cohn CS, Reding M, Bejanyan N, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015;50:1432\u20137.","DOI":"10.1038\/bmt.2015.162"},{"key":"2022091918191485160_j_med-2021-0368_ref_011","doi-asserted-by":"crossref","unstructured":"Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010;95:1183\u201390.","DOI":"10.3324\/haematol.2009.016758"},{"key":"2022091918191485160_j_med-2021-0368_ref_012","doi-asserted-by":"crossref","unstructured":"Seber A, Shu XO, Defor T, Sencer S, Ramsay N. Risk factors for severe hemorrhagic. cystitis following BMT. Bone Marrow Transplant. 1999;23:35\u201340.","DOI":"10.1038\/sj.bmt.1701523"},{"key":"2022091918191485160_j_med-2021-0368_ref_013","doi-asserted-by":"crossref","unstructured":"Lee GW, Lee JH, Choi SJ, Kim S, Seol M, Kim WK, et al. Hemorrhagic cystitis. following allogeneic hematopoietic cell transplantation. J Korean Med Sci. 2003;18:191\u20135.","DOI":"10.3346\/jkms.2003.18.2.191"},{"key":"2022091918191485160_j_med-2021-0368_ref_014","doi-asserted-by":"crossref","unstructured":"Gargiulo G, Orlando L, Alberani F, Crabu G, Di Maio A, Duranti L, et al. Haemorrhagic cystitis in haematopoietic stem cell transplantation (HSCT): a prospective observational study of incidence and management in HSCT centres within the GITMO network (Gruppo Italiano Trapianto Midollo Osseo). Ecancermedicalscience. 2014;8:420.","DOI":"10.3332\/ecancer.2014.420"},{"key":"2022091918191485160_j_med-2021-0368_ref_015","doi-asserted-by":"crossref","unstructured":"Ringd\u00e9n O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993;81:1094\u2013101.","DOI":"10.1182\/blood.V81.4.1094.bloodjournal8141094"},{"key":"2022091918191485160_j_med-2021-0368_ref_016","doi-asserted-by":"crossref","unstructured":"Prentice HG, Blacklock HA, Janossy G, Gilmore MJ, Price-Jones L, Tidman N, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet. 1984;1:472\u20136.","DOI":"10.1016\/S0140-6736(84)92848-4"},{"key":"2022091918191485160_j_med-2021-0368_ref_017","doi-asserted-by":"crossref","unstructured":"Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood. 2001;98:1971\u20138.","DOI":"10.1182\/blood.V98.6.1971"},{"key":"2022091918191485160_j_med-2021-0368_ref_018","doi-asserted-by":"crossref","unstructured":"Wong AS, Chan KH, Cheng VC, Yuen KY, Kwong YL, Leung AY, et al. Relationship of pretransplantation polyoma BK virus serologic findings and BK viral reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2007;44:830\u20137.","DOI":"10.1086\/511863"},{"key":"2022091918191485160_j_med-2021-0368_ref_019","doi-asserted-by":"crossref","unstructured":"Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R. BK Polyomavirus: clinical aspects, immune regulation, and emerging therapies. Clin Microbiol Rev. 2017;30:503\u201328.","DOI":"10.1128\/CMR.00074-16"},{"key":"2022091918191485160_j_med-2021-0368_ref_020","doi-asserted-by":"crossref","unstructured":"Rimondo A, Crocchiolo R, El-Cheikh J, Bramanti S, Granata A, Furst S, et al. The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2017;52:135\u20137.","DOI":"10.1038\/bmt.2016.193"},{"key":"2022091918191485160_j_med-2021-0368_ref_021","doi-asserted-by":"crossref","unstructured":"Copelan OR, Sanikommu SR, Trivedi JS, Butler C, Ai J, Ragon BK, et al. Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation. Biol Blood Marrow Transplant. 2019;25:785\u201390.","DOI":"10.1016\/j.bbmt.2018.12.142"},{"key":"2022091918191485160_j_med-2021-0368_ref_022","doi-asserted-by":"crossref","unstructured":"Mukherjee A, Milton D, Ledesma C, Olson A, Alatrash G, et al. Influence of the intensity of the allogeneic conditioning regimen on the risk of hemorrhagic cystitis (HC) in patients receiving post-transplant cyclophosphamide (PT-Cy) as Gvhd prophylaxis. Biol Blood Marrow Transplant. 2019;25:S147\u20138.","DOI":"10.1016\/j.bbmt.2018.12.441"},{"key":"2022091918191485160_j_med-2021-0368_ref_023","doi-asserted-by":"crossref","unstructured":"Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065\u201373.","DOI":"10.1182\/blood-2005-05-2146"},{"key":"2022091918191485160_j_med-2021-0368_ref_024","doi-asserted-by":"crossref","unstructured":"Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. Ann Hematol. 2018;97:1209\u201317.","DOI":"10.1007\/s00277-018-3290-0"},{"key":"2022091918191485160_j_med-2021-0368_ref_025","doi-asserted-by":"crossref","unstructured":"Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, et al. Symptomatic BK virus infection is associated with kidney function decline and poor overall survival in allogeneic hematopoietic stem cell recipients. Am J Transpl. 2016;16:1492\u2013502.","DOI":"10.1111\/ajt.13635"},{"key":"2022091918191485160_j_med-2021-0368_ref_026","doi-asserted-by":"crossref","unstructured":"Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, et al. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transpl Infect Dis. 2015;17:822\u201330.","DOI":"10.1111\/tid.12455"},{"key":"2022091918191485160_j_med-2021-0368_ref_027","doi-asserted-by":"crossref","unstructured":"Arai Y, Maeda T, Sugiura H, Matsui H, Jo T, Ueda T, et al. Risk factors for and prognosis of hemorrhagic cystitis after allogeneic stem cell transplantation: retrospective analysis in a single institution. Hematology. 2012;17:207\u201314.","DOI":"10.1179\/1607845412Y.0000000010"},{"key":"2022091918191485160_j_med-2021-0368_ref_028","doi-asserted-by":"crossref","unstructured":"Rascon J, Verkauskas G, Pasauliene R, Zubka V, Bilius V, Rageliene L. Intravesical cidofovir to treat BK virus-associated hemorrhagic cystitis in children after hematopoietic stem cell transplantation. Pediatr Transpl. 2015;19:E111\u20134.","DOI":"10.1111\/petr.12477"},{"key":"2022091918191485160_j_med-2021-0368_ref_029","doi-asserted-by":"crossref","unstructured":"Coomes EA, Wolfe Jacques A, Michelis FV, Kim DDH, Thyagu S, Viswabandya A, et al. Efficacy of cidofovir in treatment of BK virus-induced hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2018;24:1901\u20135.","DOI":"10.1016\/j.bbmt.2018.04.009"},{"key":"2022091918191485160_j_med-2021-0368_ref_030","doi-asserted-by":"crossref","unstructured":"Peterson L, Ostermann H, Fiegl M, Tischer J, Jaeger G, Rieger CT, et al. Reactivation of polyomavirus in the genitourinary tract is significantly associated with severe GvHD and oral mucositis following allogeneic stem cell transplantation. Infection. 2016;44:483\u201390.","DOI":"10.1007\/s15010-016-0872-4"},{"key":"2022091918191485160_j_med-2021-0368_ref_031","doi-asserted-by":"crossref","unstructured":"Leung AY, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R, et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant. 2002;29:509\u201313.","DOI":"10.1038\/sj.bmt.1703415"},{"key":"2022091918191485160_j_med-2021-0368_ref_032","doi-asserted-by":"crossref","unstructured":"Ringden O, Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol. 2011;24:65\u201372.","DOI":"10.1016\/j.beha.2011.01.003"},{"key":"2022091918191485160_j_med-2021-0368_ref_033","doi-asserted-by":"crossref","unstructured":"Aronsson-Kurttila W, Baygan A, Moretti G, Remberger M, Khoein B, Moll G, et al. Placenta-derived decidua stromal cells for hemorrhagic cystitis after stem. cell transplantation. Acta Haematol. 2018;139:106\u201314.","DOI":"10.1159\/000485735"},{"key":"2022091918191485160_j_med-2021-0368_ref_034","doi-asserted-by":"crossref","unstructured":"Wang Y, Chen F, Gu B, Chen G, Chang H, Wu D. Mesenchymal stromal cells as an adjuvant treatment for severe late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2015;133:72\u20137.","DOI":"10.1159\/000362530"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0368\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T18:27:24Z","timestamp":1663612044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0368\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,7,15]]},"published-print":{"date-parts":[[2021,7,15]]}},"alternative-id":["10.1515\/med-2021-0368"],"URL":"https:\/\/doi.org\/10.1515\/med-2021-0368","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}